FDA expands approval of Revlimid® to include newly diagnosed myeloma patients

The biopharmaceutical company, Celgene Corporation, has announced that both the European Commission and the US Food and Drug Administration (FDA) have expanded the existing indication for Revlimid in combination with dexamethasone to include its use as frontline treatment for newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation. Revlimid…

Details